Skip to main content
OnPoint Now
BusinessUnited States

McKinsey Settles $650 Million Over Opioid Crisis Involvement

Consulting giant agrees to financial restitution tied to its collaboration with Purdue Pharma in opioid misbranding.

Source: bbc.co.uk1 min read
McKinsey Settles $650 Million Over Opioid Crisis Involvement
Image via bbc.co.uk

In brief

McKinsey & Company has consented to a $650 million settlement to resolve criminal allegations linked to the US opioid epidemic, marking a significant legal consequence for its actions in the pharmaceutical sector.

In a bid to address its involvement in the opioid crisis, McKinsey has reached a $650 million settlement related to its collaboration with Purdue Pharma. This amount forms part of a larger series of settlements aimed at holding companies accountable for their roles in the ongoing public health emergency. The US Department of Justice reported that McKinsey was found to have "knowingly and intentionally" conspired to assist Purdue in misbranding OxyContin, a widely abused painkiller. This included providing strategic advice to optimize sales even as opioid addiction rates soared.In response to the allegations, McKinsey offered an apology through a statement, acknowledging its failure to foresee the extensive damage caused by opioids in society. In addition, former senior partner Martin Elling is expected to plead guilty to charges of obstruction for the destruction of pertinent records. As part of the settlement, McKinsey enters a deferred prosecution agreement, allowing for the potential dismissal of charges in five years if the company meets specified criteria for reform. This move follows McKinsey's previous settlement of nearly $1 billion concerning its dealings with Purdue and other pharmaceutical entities. Purdue Pharma, the manufacturer of OxyContin, admitted to criminal charges in 2020, settling for $8.3 billion over its role in the opioid crisis, which led to widespread addiction and overdoses across the United States.Opioid use, particularly OxyContin, surged since the mid-1990s, contributing to nearly 100,000 overdose fatalities annually. Although recent data suggests a slight decrease in overdose deaths, the crisis remains a significant health concern, demanding ongoing attention and legislative reform.

Topics

More on this story